Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer

Autor: M. K. Bos, S. W. Lam, G. Motta, J. C. A. Helmijr, C. M. Beaufort, E. de Jonge, J. W. M. Martens, E. Boven, M. P. H. M. Jansen, A. Jager, S. Sleijfer

Publikováno v: Bos, M K, Lam, S W, Motta, G, Helmijr, J C A, Beaufort, C M, de Jonge, E, Martens, J W M, Boven, E, Jansen, M P H M, Jager, A & Sleijfer, S 2023, ' Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer ', Breast Cancer Research and Treatment, vol. 200, no. 2, pp. 271-279 . https://doi.org/10.1007/s10549-023-06965-5
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York

Background ESR1 mutations have been identified as mechanism for endocrine resistance and are also associated with a decreased overall survival. We assessed ESR1 mutations in circulating tumor DNA (ctDNA) for impact on outcome to taxane-based chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7aebbcd0120eb600dc370a3b31b7216
https://pure.eur.nl/en/publications/00ba171e-1ab7-4e84-bef7-427b3ddafd1e